FDA approves pralsetinib for lung cancer with RET gene fusions | FDA

FDA approves pralsetinib for lung cancer with RET gene fusions | FDA

FDA approves pralsetinib for lung cancer with RET gene fusions

Food and Drug Administration granted accelerated approval to pralsetinib (GAVRETOTM, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. More information. September 4, 2020.